home / stock / phat / phat news

PHAT News and Press, Phathom Pharmaceuticals Inc. From 11/01/22

Stock Information
Company Name: Phathom Pharmaceuticals Inc.
Stock Symbol: PHAT
Market: NYSE
Website: phathompharma.com
Menu
PHAT PHAT Quote PHAT Short PHAT News PHAT Articles PHAT Message Board
Get PHAT Alerts

News, Short Squeeze, Breakout and More Instantly...
PHAT - Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement

Up to $40 million committed, resulting in total financing of up to $300 million available to Phathom with total royalty payments capped at 2.0x invested capital Provides agreement for additional $15 million upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE) ...
PHAT - Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)

A total of 776 patients with symptomatic NERD have been enrolled and randomized in the multisite trial across the U.S. Topline data for the primary endpoint is expected in Q1 2023 with full trial results available in late-2023 NERD is the largest subcategory of gastroesoph...

PHAT - Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that detailed results from an investigation...

PHAT - Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today the company will present new data and resea...
PHAT - Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James “Jamie...

PHAT - Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

FLORHAM PARK, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will p...

PHAT - PHAT and SKYX among mid-day movers

Gainers: BBQ Holdings ( BBQ ) +46% . Verona Pharma ( VRNA ) +41% . Mersana Therapeutics ( MRSN ) +31% . SAI.TECH Global ( SAI ) +30% . Atara Biotherapeutics ( ATRA ) +28% . PubMatic ( PUBM ) +24% . RumbleON ( RM...
PHAT - FTAI, UTME and CMRA among mid-day movers

Gainers: AMTD IDEA ( AMTD ) +350% . AMTD Digital ( HKD ) +96% . Ostin Technology Group ( OST ) +67% . 36Kr Holdings ( KRKR ) +60% . Intelligent Living ( ILAG ) +41% . Liberty TripAdvisor ( LTRPB ) +40% . United Ti...

PHAT - Quoin, Context top healthcare gainers; Ontrak, Phathom lead losers' pack

Gainers: Quoin Pharmaceuticals ( QNRX ) +45% . Context Therapeutics CNTX +13% . Rhythm Pharmaceuticals RYTM +13% . Harmony Biosciences HRMY +10% . Nautilus Biotechnology NAUT +9% . Losers: Ontrak OTRK -43% . Phathom Pharmaceutical...

PHAT - Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Phathom Pharmaceuticals press release ( NASDAQ: PHAT ): Q2 GAAP EPS of -$1.33 misses by $0.30 . Net loss for the Q2 2022 was $50.9M. For further details see: Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Previous 10 Next 10